Sale | Page 11 of 13 | SpiritIndia.com

Pharmacy :: Elan Announces Proposed Offering of Senior Notes

Elan Corporation, plc (“Elan”) today announced that its wholly owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., intend to offer, subject to market conditions, US$500 million in aggregate principal amount of senior fixed rate notes due 2013 and senior floating rate notes due 2013. The notes will be offered in the United States, only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to non-U.S. persons in accordance with Regulation S under the Securities Act.

Psychology :: Spillover effect – Why we end up spending more when we think we’re saving

Ever go to a store intending to buy one item, only to leave with a cartful? Or walked out of a store after feeling you had been overcharged for something you needed? A groundbreaking new paper in the December issue of the Journal of Consumer Research is the first to comprehensively outline “spillover effect” ? that is, the tendency for consumers to spend more on a shopping trip when something they were planning to buy is deeply discounted. Similarly, an unanticipated price increase, or a decrease in quality, on a planned purchase causes overall spending to go down.

Health :: Do not unauthorized products for sexual enhancement due to potential health risks

Health Canada is advising consumers not to use the unauthorized natural health products Zimaxx, Actra-Rx, 4Everon, Vigor-25 and Nasutra because they are adulterated with pharmaceutical ingredients that should only be used under medical supervision. The use of these products could pose a serious health risk, especially for patients with existing medical conditions such as heart problems, those who are taking heart medications, or those who may be at risk for strokes.

Health :: Do not unauthorized products for sexual enhancement due to potential health risks

Health :: Ranbaxy’s Cetirizine Syrup approved in USA by FDA

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup, 5 mg/5 mL. Total annual market sales for Cetirizine Hydrochloride Syrup were $146.3 million (IMS ? MAT: June 2006).

Multiple Sclerosis :: Increased sale of Copaxone drug for multiple sclerosis – Teva

COPAXONE? is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis. Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced, in conjunction with the release of the Sanofi-Aventis group’s financial results, that global in-market sales of Copaxone? in the third quarter of 2006 grew by 15% as compared to the third quarter of 2005 and reached a record of $354 million.

Breast Implants :: Silicone gel filled breast implants for canadian women – Health Canada

Health Canada announced that it will grant licences with conditions to Inamed Corporation and Mentor Medical Systems to market their silicone gel-filled breast implants in Canada. These Class IV licences are conditional on the manufacturers meeting several requirements to ensure their devices continue to meet the safety and effectiveness requirements of the Medical Devices Regulations.

Diabetes :: FTC and FDA Act Against Internet Vendors of Fraudulent Diabetes Cures

The Federal Trade Commission (FTC) and the Food and Drug Administration (FDA), working with government agencies in Mexico and Canada, have launched a drive to stop deceptive Internet advertisements and sales of products misrepresented as cures or treatments for diabetes. The ongoing joint campaign has so far included approximately 180 warning letters and other advisories sent to online outlets in the three countries.

Diabetes :: Novartis GALIANT study – clinical trials for diabetes drug Galvus – vildagliptin

Novartis announced the start of GALIANT, a significant clinical trial set to involve more than 7,500 people in the United States comparing the investigational oral type 2 diabetes medication Galvus? (vildagliptin) with commonly prescribed anti-diabetic oral medicines called thiazolidinediones (TZDs).

Multiple Sclerosis :: Fty720 – fingolimod reduces multiple sclerosis symptoms

The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurological disease estimated to affect more than 2.5 million people worldwide.